YAMAMOTO NOBUTO has a total of 22 patent applications. Its first patent ever was published in 1990. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are SHANGHAI KEXIN BIOTECH CO LTD, ARBOR VITA CORP and A & G PHARMACEUTICAL INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Australia | 3 | |
#5 | Canada | 2 | |
#6 | China | 1 | |
#7 | Germany | 1 | |
#8 | Norway | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Machines |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Enzymes | |
#7 | Measuring microorganism processes | |
#8 | Unspecified technologies | |
#9 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Yamamoto Nobuto | 20 |
Publication | Filing date | Title |
---|---|---|
US2006014143A1 | Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis | |
WO9830906A1 | DIAGNOSTIC AND PROGNOSTIC ELISA ASSAY OF SERUM α-N-ACETYLGALACTOSAMINIDASE FOR INFLUENZA | |
EP1443112A2 | Macrophage activating factors derived from cloned vitamin D binding protein | |
US5326749A | Macrophage activating factor from vitamin D binding protein | |
US5177001A | In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor | |
US5177002A | In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor |